btw the chances of an adverse result are, to my mind, extremely improbable. It is in a proven class of drug, it has been very well tolerated across all doses so far, all bar one patient who started it is continuing on it and it has proven it's superiority in effectiveness against one of the current market leaders in HIV drugs.
The only question is, how cheap can you get the shares?
